治疗眼表疾病：正在研发的新药物
Treating ocular surface disease: new agents in development.
作者信息
Fahmy Ahmad M, Hardten David R
机构信息
University of Minnesota, Minneapolis, MN, USA.
出版信息
Clin Ophthalmol. 2011;5:465-72. doi: 10.2147/OPTH.S12291. Epub 2011 Apr 14.
Abstract
This paper reviews recent advances and investigation in the treatment of ocular surface pathology. There is significant investment in this area, paralleling the growing demand for more effective alternatives to current treatments. Clinicians are becoming more aware of surface pathology, yet the ability to treat the most common forms of ocular pathology are still limited to the few medications approved by the US Food and Drug Administration. Medicines and devices currently under investigation are very promising. It is absolutely critical to understand the emerging options and think of their role in the treatment paradigm.
摘要
本文综述了眼表疾病治疗方面的最新进展和研究情况。该领域投入巨大，这与对当前治疗方法更有效替代方案的需求不断增长相平行。临床医生对眼表疾病的认识日益提高，但治疗最常见眼表疾病形式的能力仍局限于美国食品药品监督管理局批准的少数几种药物。目前正在研究的药物和器械前景十分广阔。了解这些新出现的选择并思考它们在治疗模式中的作用至关重要。
相似文献
1
Treating ocular surface disease: new agents in development.
Clin Ophthalmol. 2011;5:465-72. doi: 10.2147/OPTH.S12291. Epub 2011 Apr 14.
2
Current options and emerging therapies for anterior ocular inflammatory disease.
Curr Opin Allergy Clin Immunol. 2014 Oct;14(5):485-9. doi: 10.1097/ACI.0000000000000097.
3
Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8642-8652. doi: 10.26355/eurrev_202009_22801.
4
From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5.
5
Pharmacoeconomics of anterior ocular inflammatory disease.
Curr Opin Allergy Clin Immunol. 2013 Oct;13(5):537-42. doi: 10.1097/ACI.0b013e328364d843.
6
Ocular medicines in children: the regulatory situation related to clinical research.
BMC Pediatr. 2012 Jan 20;12:8. doi: 10.1186/1471-2431-12-8.
7
Advances in dry eye disease treatment.
Curr Opin Ophthalmol. 2019 May;30(3):166-178. doi: 10.1097/ICU.0000000000000569.
8
Isolation of the ocular surface to treat dysfunctional tear syndrome associated with computer use.
Ocul Surf. 2007 Oct;5(4):308-15. doi: 10.1016/s1542-0124(12)70096-4.
9
Flavonoid and cannabinoid impact on the ocular surface.
Curr Opin Allergy Clin Immunol. 2020 Oct;20(5):482-492. doi: 10.1097/ACI.0000000000000673.
10
[Research and development for treating devastating corneal diseases].
Nippon Ganka Gakkai Zasshi. 2010 Mar;114(3):161-99; discussion 200-1.
引用本文的文献
1
Effects of diquafosol sodium in povidone iodine-induced dry eye model.
Int J Ophthalmol. 2023 Dec 18;16(12):1919-1927. doi: 10.18240/ijo.2023.12.02. eCollection 2023.
2
Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.
Curr Opin Ophthalmol. 2017 Jan;27 Suppl 1(Suppl 1):3-47. doi: 10.1097/01.icu.0000512373.81749.b7.
3
Burning Eye Syndrome: Do Neuropathic Pain Mechanisms Underlie Chronic Dry Eye?
Pain Med. 2016 Apr;17(4):746-55. doi: 10.1093/pm/pnv070. Epub 2015 Dec 24.
4
Escherichia coli Nissle 1917 bacterial ghosts retain crucial surface properties and express chlamydial antigen: an imaging study of a delivery system for the ocular surface.
Drug Des Devel Ther. 2015 Jul 21;9:3741-54. doi: 10.2147/DDDT.S84370. eCollection 2015.
5
New agents for treating dry eye syndrome.
Curr Allergy Asthma Rep. 2013 Jun;13(3):322-8. doi: 10.1007/s11882-012-0321-0.
本文引用的文献
1
Novel anti-inflammatory--pro-resolving mediators and their receptors.
Curr Top Med Chem. 2011;11(6):629-47. doi: 10.2174/1568026611109060629.
2
Comorbidities of dry eye disease: a nationwide population-based study.
Acta Ophthalmol. 2012 Nov;90(7):663-8. doi: 10.1111/j.1755-3768.2010.01993.x. Epub 2010 Aug 31.
3
Cytokine and chemokine levels in tears from healthy subjects.
Acta Ophthalmol. 2010 Nov;88(7):e250-8. doi: 10.1111/j.1755-3768.2010.01978.x. Epub 2010 Aug 25.
4
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Ophthalmology. 2010 Jul;117(7):1287-93. doi: 10.1016/j.ophtha.2009.11.029. Epub 2010 Mar 20.
5
Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis.
Biochem Pharmacol. 2010 Jun 1;79(11):1622-33. doi: 10.1016/j.bcp.2010.01.030. Epub 2010 Feb 2.
6
Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Surv Ophthalmol. 2009 Nov-Dec;54(6):686-96. doi: 10.1016/j.survophthal.2009.03.004. Epub 2009 Aug 21.
7
CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
Curr Opin Investig Drugs. 2009 May;10(5):491-504.
8
[Safety of treatment with tacrolimus ointment for anterior segment inflammatory diseases].
Klin Monbl Augenheilkd. 2009 Apr;226(4):234-6. doi: 10.1055/s-0028-1109328. Epub 2009 Apr 21.
9
Topical omega-3 and omega-6 fatty acids for treatment of dry eye.
Arch Ophthalmol. 2008 Feb;126(2):219-25. doi: 10.1001/archophthalmol.2007.61.
10
Treatment of ocular inflammatory conditions with loteprednol etabonate.
Br J Ophthalmol. 2008 Apr;92(4):455-9. doi: 10.1136/bjo.2007.132621. Epub 2008 Feb 1.
Zotero 插件